Stryker Corporation’s Australian division is recommending that all patients implanted with the Stryker ABG II modular hip replacement system receive regular blood testing and cross-sectional imaging of the hip implant site. This recommendation comes after the manufacturer issued a global recall of the Stryker Rejuvenate and Stryker ABG II hip replacement systems in July 2012.
Stryker Corporation recalled the Rejuvenate and ABG II hip replacement systems after the hip replacements were linked to an increased risk of fretting and corrosion, hip implant dislocation, fractures, bone deterioration and metal poisoning. Patients implanted with Stryker hip replacements have reported experiencing symptoms such as pain, swelling and difficulty walking.
Initially, Stryker recommended that Australian physicians conduct blood testing only if patients experienced symptoms of hip implant failure. The manufacturers are now recommending that all patients with ABG II implants, regardless of symptoms experienced, receive regular blood testing and imaging to ensure that metal debris from the metal-on-metal hip replacement system has not entered the bloodstream.